Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 67Pancreatic Neoplasms 34Neoplasm Metastasis 22Neuroblastoma 21Neoplasms 16Colonic Neoplasms 15Stomach Neoplasms 13Rectal Neoplasms 13Sarcoma, Ewing 8Rhabdomyosarcoma 8Esophageal Squamous Cell Carcinoma 8Small Cell Lung Carcinoma 7Sarcoma 7Ovarian Neoplasms 6Lung Neoplasms 6Cholangiocarcinoma 6Esophageal Neoplasms 5Breast Neoplasms 5Adenocarcinoma Of Esophagus 5Medulloblastoma 4Gastrointestinal Neoplasms 4Endometrial Neoplasms 4Biliary Tract Neoplasms 4Adenocarcinoma 4Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Osteosarcoma 3Glioma 3Glioblastoma 3Ganglioneuroblastoma 3

Interventions

Nivolumab 2pembrolizumab 1folfirinox 1durvalumab 1Trastuzumab 1Single Person 1Paclitaxel 1Irinotecan 1IFL protocol 1Folfox protocol 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastroesophageal Adenocarcinoma × Irinotecan × 1 year × Clear all
NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

University of California, Irvine

Phase 1 Recruiting
20 enrolled
Gastrointestinal

Gastroesophageal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡